InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$790.74

2026-10-16

Market Cap

$81.4B

Volume

0.7M

52-Wk High

$859.34

52-Wk Low

$566.11

Trailing PE

18.9

P/S

5.24

Gross Margin

84.9%

Net Margin

27.9%

ROE

14%

ROIC

9%

Piotroski

7/9

Altman Z

7.3

1-Yr Return

+39.1%

5-Yr Return

+168.6%

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

SectorHealthcareIndustryBiotechnologyExchangeNASDAQMarket Cap$81.4BEmployees15,410 (SEC-filed)CEOLeonard S. SchleiferIPO1991-04-02CountryUS

777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 · Tel 914 847 7000 · regeneron.com

INSIDERSTREET SCORE68 / 100Street mean $849.39 (18 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$7M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · REGN +39.1% · S&P 500 +15.9% · spread +23.2pp

7 Years vs S&P 500 · REGN +168.6% · S&P 500 +189.9% · spread -21.3pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE68of 100

Score Breakdown

Profitability	82/100
Growth	45/100
Momentum	67/100
Quality	85/100
Earnings Quality	68/100
Balance Sheet	97/100
Value	69/100
Risk (safety)	100/100
Overall	68.4/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
MRNA	30
VRTX	76
ARGX	74
ONC	78
ALNY	68
ROIV	38
REGN	68

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 73 in 25 Q2, latest 68 — -5 since. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY68 / 100IS Score 68.4 / 100 · -5.1 from peak of 73

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 76 / 100 · Power +51 · 21 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 68 and price structure at 76 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 68.4	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 72 → 69 → 71 → 68	the direction matters more than the level
Technical vote share back above 50%	now 91%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,398 → now 1,340	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)2 buys2026-07-07

Insider Buys (180d)0none disclosed

ETF Funds (30d)1489 up / 1361 downnet +128 funds

Institutions Added (13F)-58managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,398 · latest 1,340 (-58 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,340	92.3M	$55.7B	89.3%
2026 Q1	1,398	88.8M	$66.2B	85.9%
2025 Q4	1,382	89.9M	$66.8B	87.0%
2025 Q3	1,240	87.1M	$47.8B	84.2%
2025 Q2	1,201	89.5M	$46.2B	86.5%
2025 Q1	1,287	93.3M	$56.4B	90.3%
2024 Q4	1,313	93.5M	$63.6B	90.4%
2024 Q3	1,387	93.9M	$94.3B	90.8%
2024 Q2	1,327	94.2M	$96.2B	91.1%
2024 Q1	1,310	93.3M	$86.7B	90.2%
2023 Q4	1,267	91.3M	$78.3B	88.3%
2023 Q3	1,171	90.9M	$71.8B	87.9%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	6	$0.00M	51,974
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	35	$0.03M	51,939
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	16	$0.01M	51,923
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	24	$0.02M	51,899
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	14	$0.01M	51,885
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	74	$0.06M	51,811
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	27	$0.02M	51,784
Murphy Andrew J	Co-Chief Scientific Officer	2026-10-14	SELL	55	$0.04M	51,729

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	67	8,593	$6.9M	Counted
M — Exercises (paired A/D)	6	37,165	$14.5M	None — mechanics
F — Tax withholding	3	26,471	$20.9M	None — compensation
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$6.9M67 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-10-14	Murphy Andrew J	4,147	$3.2M
2026-08-10	Zoghbi Huda Y	800	$0.6M
2026-08-10	Guarini Kathryn	400	$0.3M
2026-07-02	Arthur F. Ryan	400	$0.2M
Trailing 12 mo	11 filings	19,012	$14M

Filed	Form	Reporting person	% of class	Shares
2026-04-30	SCHEDULE 13G	Vanguard Capital Management	7.37%	7.7M sh
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change
2025-08-06	SCHEDULE 13G/A	Abigail P. Johnson	3.20%	3.4M sh
2025-06-05	SCHEDULE 13G/A	JPMORGAN CHASE & CO.	4.40%	4.7M sh

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	SELL	$1,001 - $15,000	2026-09-04	2026-10-09
Ro Khanna	House	BUY	$1,001 - $15,000	2026-07-07	2026-08-12
Gilbert Cisneros	House	SELL	$1,001 - $15,000	2026-05-15	2026-06-09
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-21
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2024-04-04	2024-05-15
Tommy Tuberville	Senate	SELL	$1,001 - $15,000	2024-04-04	2024-05-14

House 12-Mo11 trades6 purchases

Senate 12-Mo1 trades1 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,398

13F Shares89M85.9% of shares out

New / Closed141 / 98positions, QoQ

Increased / Reduced578 / 458positions, QoQ

Put/Call (13F)0.88option positions

Free Float96.2%99M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Jia Investment Alliance Pte. Ltd.	67,300	$51M
Atwood & Palmer Inc	42,454	$32M
Fjarde Ap-Fonden /Fourth Swedish N	40,105	$30M
Wealth Enhancement Advisory Servic	37,200	$20M
Assenagon Asset Management S.A.	36,881	$28M
Wedge Capital Management L L P/Nc	33,733	$26M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$2.4B
VTSAX	0.1%	$2.4B
VSMPX	0.1%	$2.4B
VTI	0.1%	$2.4B
VOO	0.1%	$2.0B
VFIAX	0.1%	$2.0B

13F Filers Holding REGN — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session50.0%2026-10-15

20-Day Avg47.4%50-day 51.1%

TrendFalling20d vs 50d

By Market CenterQ: 50% · N: 62% · B: 25%latest session

Weekly Notional ($B)

Where REGN Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	0.9M	20 sh
Ubsa Ubs Ats	0.7M	22 sh
Sgmt Sigma X2	0.5M	18 sh
Mlix Instinct X	0.4M	29 sh
Ebxl Level Ats	0.3M	11 sh
Cgxs Onechronos	0.3M	31 sh

Where a dollar of Regeneron Pharmaceuticals, Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$4.4B	90%
Rest Of World	$508M	10%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

REGN (live moat model)Peer median: MRNA · VRTX · ARGX · ONC · ALNY

Component scores from the live moat model. Peer median illustrative.

Moat score 55/100 — Narrow; primary source Switching Costs.

3.8 · Employees (SEC filings)

Officer	Title
Leonard S. Schleifer	Co-Founder, President, Chief Executive Officer & Co-Chairman
George D. Yancopoulos	Co-Founder, President, Chief Scientific Officer & Co-Chairman
Joseph J. LaRosa	Executive Vice President, General Counsel & Secretary
Daniel Van Plew	Executive Vice President and GM of Industrial Operations & Product Supply

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+20.7%

Next Report2026-10-30

Income Quality1.03OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+89.1%	-24.3%	+7.8%	+8.3%	+1.0%
Gross profit	+86.9%	-21.6%	+3.9%	+12.5%	+0.1%
Operating income	+150.1%	-39.8%	-19.3%	-8.2%	-10.3%
Net income	+129.9%	-46.3%	-8.9%	+11.6%	+2.1%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	16.1	12.2	13.1	14.2	14.3
Cost of revenue	2.7	1.7	2.2	2.0	2.1
Gross profit	13.3	10.5	10.9	12.2	12.2
R&D expense	2.6	3.1	4.0	5.2	5.9
SG&A expense	1.8	2.1	2.5	3.0	2.7
Operating income	8.9	5.4	4.3	4.0	3.6
EBITDA	9.7	5.3	4.7	5.3	5.8
D&A	0.3	0.3	0.4	0.5	0.5
Pretax income	9.3	4.9	4.2	4.8	5.2
Income tax	1.3	0.5	0.2	0.4	0.7
Net income	8.1	4.3	4.0	4.4	4.5
Diluted EPS ($)	71.97	38.22	34.77	38.34	41.48
Diluted shares (M)	112	114	114	115	109

Operating CF$5B

CapEx$1B

Free cash flow$4B

SBC$1B

Buybacks$3B

Net cash change$1B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	3.1	2.7	2.5	3.1
ST investments	4.6	8.1	6.5	5.5
Receivables (net)	5.3	5.7	6.2	5.7
Total current assets	15.9	19.5	18.7	18.0
PP&E (net)	3.8	4.1	4.6	5.1
Goodwill + intangibles	0.9	1.0	1.1	1.3
Total assets	29.2	33.1	37.8	40.6
Accounts payable	0.6	0.6	0.8	0.9
Short-term debt	0.0	0.0	0.0	0.0
Deferred revenue	0.5	0.5	0.6	0.6
Total current liabilities	3.1	3.4	3.9	4.4
Long-term debt	2.0	2.0	2.0	2.0
Total liabilities	6.6	7.1	8.4	9.3
Shareholders' equity	22.7	26.0	29.4	31.3

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	4.3	4.0	4.4	4.5
D&A	0.3	0.4	0.5	0.5
Stock-based compensation	0.7	0.9	1.0	1.0
Working capital change	(0.2)	(0.1)	(0.6)	0.5
Operating cash flow	5.0	4.6	4.4	5.0
Capital expenditures	(0.6)	(0.9)	(0.8)	(0.9)
Investing cash flow	(3.8)	(3.2)	(2.5)	(0.6)
Buybacks	(2.5)	(2.9)	(3.6)	(3.4)
Dividends paid	0.0	0.0	0.0	(0.4)
Debt issuance / (repay)	0.0	0.0	0.0	0.0
Financing cash flow	(1.0)	(1.8)	(2.2)	(3.7)
Free cash flow	4.4	3.7	3.7	4.1

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	54.2%	20.9%	16.3%	16.0%	14.9%	14%
ROA	37.9%	15.9%	12.7%	12.5%	11.5%	10.4%
ROIC	49.1%	26.0%	22.6%	16.0%	12.2%	9.2%
Gross margin	83.1%	86.0%	82.9%	86.1%	85.4%	84.9%
Operating margin	55.7%	44.2%	33.2%	28.1%	24.9%	25.6%
Net margin	50.2%	35.6%	30.1%	31.1%	31.4%	27.9%
EBITDA margin	60.2%	43.2%	35.8%	37.4%	40.6%	37.0%
FCF margin	40.6%	36.3%	29.1%	25.3%	28.4%	—
VALUATION
P/E	8.80	18.85	25.14	18.27	18.42	18.9
P/B	3.79	3.61	3.83	2.75	2.65	2.6
P/S	4.42	6.72	7.58	5.68	5.79	5.24
P/FCF	10.89	18.49	26.07	22.41	20.33	23.1
EV/EBITDA	7.04	14.59	19.44	13.97	13.25	14.1
EV/Revenue	4.24	6.31	6.96	5.23	5.37	5.2
Earnings yield	11.4%	5.3%	4.0%	5.5%	5.4%	5.29%
FCF yield	9.2%	5.4%	3.8%	4.5%	4.9%	4.33%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	3.56	5.06	5.69	4.73	4.13	3.34
Quick ratio	3.07	4.29	4.94	3.95	3.39	2.78
Debt / equity	0.14	0.12	0.10	0.09	0.09	0.06
Debt / assets	10.6%	9.2%	8.2%	7.2%	6.7%	4.8%
Net debt / EBITDA	-0.31	-0.96	-1.73	-1.19	-1.01	-0.08
Interest coverage	163.75	82.80	58.52	87.59	120.42	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.75	0.45	0.42	0.40	0.37	0.37
Receivables turnover	3.17	2.14	2.39	2.39	2.40	2.4
DSO (days)	115	170	153	153	152	154
DPO (days)	70	119	98	129	150	180
Cash conversion cycle	305	501	462	548	548	453
GROWTH (YoY)
Revenue growth	89.1%	-24.3%	7.8%	8.3%	1.0%	—
Net income growth	129.9%	-46.3%	-8.9%	11.6%	2.1%	—
EPS growth	127.9%	-46.7%	-8.7%	11.6%	8.1%	—
FCF growth	225.9%	-32.2%	-13.8%	-5.7%	13.4%	—
PER SHARE ($)
EPS (diluted, TTM)	71.34	38.06	34.74	38.78	41.91	41.86
Book value / share	165.80	198.81	228.23	257.94	290.76	306.68
Revenue / share	141.98	106.78	115.27	124.80	133.42	150.24
FCF / share	57.68	38.81	33.51	31.61	37.96	34.06
Cash / share	50.31	67.91	95.30	79.20	80.05	77.32
SHAREHOLDER RETURN & SCORES
Buyback yield	3.8%	3.1%	3.0%	3.9%	4.1%	4.95%
Altman Z-Score	9.77	10.10	10.95	8.20	7.77	7.3
Piotroski F-Score	5	6	7	8	5	7/9
Beneish M-Score	-1.36	-2.71	-2.51	-2.24	-2.52	-2.31

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	7.3	Safe (>2.99)	Safe
Income quality	1.03	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.31	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.84
Interest burden	0.99
Operating margin	33.6%
Asset turnover	0.39×
Financial leverage	1.30×
= ROE	14%

Growth Quality (live)	Value
Revenue stability	0.87
Earnings stability	0.69
Earnings persistence	0.99
Revenue CAGR 3y	7.0%
EPS CAGR 3y	2.4%
FCF CAGR 3y	-5.3%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield4.95%

Dividend Yield0.47%

Total Shareholder Return4.38%cash yield

SBC / Revenue6.4%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
MRNA	$87.0B	-27.3	-39%	—	-27.2%	2/9	+758.6%
VRTX	$126.7B	28.9	24%	33.0%	+10.6%	6/9	+22.3%
ARGX	$51.5B	29.6	47%	29.8%	+242.1%	5/9	-2.2%
ONC	$39.4B	25.6	15%	13.9%	+34.3%	8/9	+16.0%
ALNY	$31.0B	38.0	101%	12.7%	+95.1%	6/9	—
ROIV	$24.2B	-88.2	-6%	—	-67.6%	1/9	—
INCY	$22.9B	13.9	31%	35.0%	+26.9%	8/9	—
UTHR	$22.9B	17.6	19%	42.5%	+2.5%	6/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

49 Analysts

Str Sell (0)Sell (0)Hold (14)Buy (35)Str Buy (0)

Mean Target (qtr)$849.3918 targets

Target vs. Price+7.4%last-quarter mean

Next Report2026-10-30street $16.06

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$17.56B	$19.00B / $15.77B	$58.55	$64.88 / $44.28	15
FY2027	$18.74B	$20.16B / $16.96B	$62.56	$67.39 / $51.54	9
FY2028	$20.09B	$22.62B / $17.65B	$69.66	$78.32 / $61.43	7

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$869.75	+10.0%	8
Last Quarter	$849.39	+7.4%	18
Last Year	$823.93	+4.2%	72
All Time	$863.97	+9.3%	153

Rolling mean of published targets vs. last close $790.74. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

A

DCF

5/5

ROE

4/5

ROA

5/5

Debt/Eq

3/5

P/E

3/5

P/B

3/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

REGN +39.1% vs S&P 500 +15.9% — spread +23.2pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$764.69	+26.05	+3.41%	Above
SMA 50	$790.72	+0.02	+0.00%	Above
SMA 200	$735.17	+55.57	+7.56%	Above
EMA 9	$769.58	+21.16	+2.75%	Above
EMA 21	$768.52	+22.22	+2.89%	Above
EMA 50	$765.86	+24.88	+3.25%	Above
EMA 200	$728.64	+62.10	+8.52%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +5121 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%100

Momentum 25%90

Volume 20%62

Volatility 10%33

Patterns 15%50

This Week91% bullishof 11 price-based votes

4 Weeks Ago27%+64 pts since

12 Weeks Ago36%+55 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$764.69

Price vs SMA 50$790.72

Price vs SMA 200$735.17

EMA 9/21 Cross769.6/768.5

SMA 50/200Golden

ADX DirectionADX 18

Supertrend$733

Parabolic SAR$736

SMA Slope0.290

RSI57.2

Stochastic K/D77/64

StochRSI K/D97/90

Williams %R-21

CCI83

TSI vs Signal-3.6

CMO14.3

ROC7.55%

OBV SignalAccum

Chaikin MF0.000

MFI50

Force Index3M

Elder Ray Bull35.63

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 64

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$799.47 / $806.36 / $816.38	S1 / S2	$789.45 / $782.56
Bollinger (20,2)	$713.05 – $816.33	Squeeze	Off
52-wk range	$563.30 – $859.34	Off 52-wk high	-8.0%
ATR (14)	$21.66 (2.7%)	Historical vol	29.4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+1.5%Jan45%

+0.6%Feb60%

+2.3%Mar62%

+0.7%Apr45%

+0.9%May65%

-2.7%Jun40%

+7.1%Jul75%

+5.0%Aug70%

-0.8%Sep40%

-0.6%Oct40%

+4.2%Nov65%

+2.3%Dec50%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	REGN	S&P 500
Weekly volatility (σ, 1y)	4.51%	1.83%
Best / worst week (1y)	+13.6% / -8.4%	—
Max drawdown (5y, monthly)	-56.0%	—
1-week VaR (95%)	-7.8%	—
Beta (5y)	0.24	1.00

REGN EQUITY WEATHER (LIVE)CLOUDY · +1

Trend+33

Momentum+45

Volume-43

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 352 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+0.5+38.1 vs industry

Trend+33.2+72.7 vs industry

Momentum+44.9+93.4 vs industry

Volume-43.0-4.2 vs industry

Reading	REGN	Biotechnology n=1,668	Healthcare n=5,272	All US symbols n=70,435
Overall	+0.5	-37.6	-24.0	-20.5
Trend	+33.2	-39.5	-25.6	-21.3
Momentum	+44.9	-48.5	-28.5	-15.8
Volume	-43.0	-38.8	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Daniel P. Van Plew Executive Vice President	$8.8M	42% equity+incentive
Andrew J. Murphy, Ph.D. Executive Vice Presi	$8.5M	41% equity+incentive
Joseph J. LaRosa Executive Vice President, G	$7.5M	36% equity+incentive
Leonard S. Schleifer, M.D., Ph.D. Board co-C	$7.3M	51% equity+incentive
Christopher Fenimore Executive Vice Presiden	$7.0M	42% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	48
Social	47
Governance	55
Composite ESG	50

Composite ESG Trend

Filed	8-K contents	Items
2026-10-06	Material Agreement; Earnings Release; Other Events	1.01,2.02,8.01
2026-09-30	Officer/Director Change; Exhibits	5.02,9.01
2026-07-30	Earnings Release; Exhibits	2.02,9.01
2026-07-06	Earnings Release	2.02
2026-06-17	Shareholder Vote	5.07
2026-04-29	Earnings Release; Exhibits	2.02,9.01
2026-04-08	Earnings Release	2.02
2026-01-30	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-11-05 to 2026-07-30
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	113 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-10-14
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-06-05 to 2026-04-30
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Regeneron Pharmaceuticals, Inc. (REGN)

Institutions holding — 12 quarters

Regeneron Pharmaceuticals, Inc. (REGN)

Monthly Net Insider Flow (000 shares)

Signal Summary

Regeneron Pharmaceuticals, Inc. (REGN)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding REGN — quarterly

Institutional Put/Call — quarterly

Regeneron Pharmaceuticals, Inc. (REGN)

Where REGN Trades in the Dark

Regeneron Pharmaceuticals, Inc. (REGN)

3.8 · Employees (SEC filings)

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN)

Balance Sheet — Full

Cash Flow Statement — Full

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN)

Street Price Target — Trajectory

Third-Party Composite Rating

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN)

Family Scores (site weights)

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. (REGN)